Management of relapsing–remitting multiple sclerosis in Qatar: an expert consensus

References

• Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019;15(1):53–58.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Bermel R, Phillips T, et al. A brief history of NEDA. Mult Scler Relat Disord. 2018;20:228–230.
   PubMed Web of Science ®Google Scholar
• Deleu D, Mesraoua B, El Khider H, et al. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. Curr Med Res Opin. 2017;33(3):439–458.
   PubMed Web of Science ®Google Scholar
• Qatar Ministry of Development and Statistics [Internet] [cited 2019 Mar]. Available from: https://www.mdps.gov.qa/en/Pages/default.aspx
   Google Scholar
• Akhtar N, Elsetouhy A, Deleu D, et al. Newly diagnosed multiple sclerosis in state of Qatar. Clin Neurol Neurosur. 2013;115(8):1333–1337.
   PubMed Web of Science ®Google Scholar
• Deleu D, Mir D, Al Tabouki A, et al. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler. 2013;19(6):816–819.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. A reassessment of the distribution of multiple sclerosis – part 1. Acta Neurol Scand. 2009;51(2):110–136.
   Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25(2):215–237.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis [Internet] [cited 2019 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf
   Google Scholar
• European Medicines Agency. Assessment report. Mavenclad [Internet] [cited 2019 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004230/WC500234563.pdf
   Google Scholar
• Gilenya (fingolimod hydrochloride) European Summary of Product Characteristics [Internet] [cited 2019 Mar]. Available from: https://www.medicines.org.uk/emc/product/4545
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Summary of opinion (post authorisation). Tysabri. 30 May 2013. Natalizumab [Internet] [cited 2019 Mar]. Available from: https://www.ema.europa.eu/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri_en-0.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Summary of opinion (initial authorisation). Gilenya. Fingolimod. 20 January 2011. EMA/26661/2011 [Internet] [cited 2019 Mar]. Available from: https://www.ema.europa.eu/documents/press-release/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-january-2011_en.pdf
   Google Scholar
• Tysabri (natalizumab) European Summary of Product Characteristics [Internet] [cited 2019 Mar]. Available from: https://www.medicines.org.uk/emc/product/222
   Google Scholar
• Zakaria M. Smoke and mirrors: limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2015;4(3):187–191.
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285–294.
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon β-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657–665.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–1276.
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol. 2013;73(6):705–713.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Kappos L, et al. BG-12 Increases the proportion of patients free of clinical and radiologic disease activity in relapsing–remitting multiple sclerosis: findings from the DEFINE Study. Neurology. 2012;78(Meeting Abstracts 1):PD5.005.
   Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–1828.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S; CLARITY Study Group, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–337.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, t al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–260.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Arnold D, Bar-Or A, et al. Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies (PL02.004). Neurology. 2016;86(Suppl 1):Abstract PL02:004.
   Google Scholar
• Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014;71(3):269–270.
   PubMed Web of Science ®Google Scholar
• Sanford M, Lyseng-Williamson KA. Subcutaneous recombinant interferon-β-1a (Rebif): a review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2011;71(14):1865–1891.
   PubMed Web of Science ®Google Scholar
• Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf. 2000;22(2):149–159.
   PubMed Web of Science ®Google Scholar
• Reder AT, Oger JF, Kappos L, et al. Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Mult Scler Relat Disord. 2014;3(3):294–302.
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing–remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010;70(12):1545–1577.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Neuhaus O, Hohlfeld R. Risk–benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 2001;24(13):979–990.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Dimethyl fumarate: a review in relapsing–remitting MS. Drugs. 2016;76(2):243–254.
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253–265.
   PubMed Web of Science ®Google Scholar
• Mills EA, Ogrodnik MA, Plave A, et al. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol. 2018;9:5.
   PubMed Web of Science ®Google Scholar
• Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. Ther Adv Neurol Disord. 2017;10(12):381–396.
   PubMed Web of Science ®Google Scholar
• Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. TCRM. 2017;13:871–879.
   Web of Science ®Google Scholar
• Deeks ED. Cladribine tablets: a review in relapsing MS. CNS Drugs. 2018;32(8):785–796.
   PubMed Web of Science ®Google Scholar
• Cook S, Leist T, Comi G, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157–167.
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e158.
   PubMed Web of Science ®Google Scholar
• Rudick R, Polman C, Clifford D, et al. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70(2):172–182.
   PubMed Web of Science ®Google Scholar
• Clerico M, Artusi CA, Liberto AD, et al. Natalizumab in multiple sclerosis: long-term management. IJMS. 2017;18(5):940.
   Web of Science ®Google Scholar
• Lanza Cariccio V, Bramanti P, Mazzon E. Biomarkers identification for PML monitoring, during natalizumab (Tysabri) treatment in relapsing–remitting multiple sclerosis. Mult Scler Relat Disord. 2018;20:93–99.
   PubMed Web of Science ®Google Scholar
• Ocrevus (ocrelizumab) European Summary of Product Characteristics [Internet] [cited 2019 Mar]. Available from: https://www.medicines.org.uk/emc/product/8898
   Google Scholar
• McCool R, Wilson K, Arber M, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:55–61.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9(1):44–52.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156–1164.
   PubMed Web of Science ®Google Scholar
• Tuccori M, Focosi D, Blandizzi C, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010;15(11):1214–1219.
   PubMed Web of Science ®Google Scholar
• Behjati M, Etemadifar M, Abdar Esfahani M. Cardiovascular effects of fingolimod: a review article. Iran J Neurol. 2014;13(3):119–126.
   PubMedGoogle Scholar
• Druart C, El Sankari S, van Pesch V. Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. PROM. 2017;9:1–10.
   Google Scholar
• Mandal P, Gupta A, Fusi-Rubiano W, et al. Fingolimod: therapeutic mechanisms and ocular adverse effects. Eye (Lond). 2017;31(2):232–240.
   PubMed Web of Science ®Google Scholar
• Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90(20):e1815–e1821.
   PubMed Web of Science ®Google Scholar
• Boyko AN, Boyko OV. Cladribine tablets’ potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2018;8:35–44.
   PubMed Web of Science ®Google Scholar
• Willis MD, Robertson NP. Alemtuzumab for the treatment of multiple sclerosis. Ther Clin Risk Manag. 2015;11:525–534.
   PubMed Web of Science ®Google Scholar
• Fyfe I. Multiple sclerosis: immune reconstitution effective for MS. Nat Rev Neurol. 2016;12(8):429.
   PubMedGoogle Scholar
• Karussis D, Petrou P. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunol Res. 2018;66(6):642.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594–1604.
   PubMed Web of Science ®Google Scholar
• Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28–35.
   PubMed Web of Science ®Google Scholar
• Newsome SD, Aliotta PJ, Bainbridge J, et al. CME/CNE article: a framework of care in multiple sclerosis, part 1: updated disease classification and disease-modifying therapy use in specific circumstances. Int J MS Care. 2016;18(6):314–323.
   PubMedGoogle Scholar
• Newsome SD, Aliotta PJ, Bainbridge J, et al. A framework of care in multiple sclerosis, part 2: symptomatic care and beyond. Int J MS Care. 2017;19(1):42–56.
   PubMedGoogle Scholar
• Kamm CP, Muehl S, Mircsof D, et al. Role of family planning in women with multiple sclerosis in switzerland: results of the Women With Multiple Sclerosis Patient Survey. Front Neurol. 2018;9:821.
   PubMed Web of Science ®Google Scholar
• Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351–2374.
   PubMed Web of Science ®Google Scholar
• Havla J, Kleiter I, Kümpfel T. Bridging, switching or drug holidays – how to treat a patient who stops natalizumab? Ther Clin Risk Manag. 2013;9:361–369.
   PubMed Web of Science ®Google Scholar
• Hoepner R, Havla J, Eienbröker C, et al. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Mult Scler. 2014;20(13):1714–1720.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329–333. l
   PubMed Web of Science ®Google Scholar
• Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19(2):106–114.
   PubMedGoogle Scholar
• Al-Oballi Kridli S, Ilori OM, Verriest HL, et al. Health beliefs and practices related to pregnancy and childcare in Qatar: a qualitative study. J Nurs Educ Pract. 2013;3:1–10.
   Google Scholar
• Alroughani R, Altintas A, Al Jumah M, et al. Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks. Mult Scler Int. 2016;2016:1034912.
   PubMed Web of Science ®Google Scholar
• Wundes A, Pebdani RN, Amtmann D. What do healthcare providers advise women with multiple sclerosis regarding pregnancy? Mult Scler Int. 2014;2014:819216.
   PubMedGoogle Scholar
• Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9(3):198–210.
   PubMed Web of Science ®Google Scholar
• Kantor D, Bright JR, Burtchell J. Perspectives from the patient and the healthcare professional in multiple sclerosis: social media and participatory medicine. Neurol Ther. 2018;7(1):37–49.
   PubMed Web of Science ®Google Scholar
• Members of the MS in the 21st Century Steering Group. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord. 2018;19:153–160.
   PubMed Web of Science ®Google Scholar
• Garcia-Dominguez JM, Muñoz D, Comellas M, et al. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. PPA. 2016;10:1945–1956.
   Web of Science ®Google Scholar
• Mansfield C, Thomas N, Gebben D, et al. Preferences for multiple sclerosis treatments: using a discrete-choice experiment to examine differences across subgroups of US patients. Int J MS Care. 2017;19(4):172–183.
   PubMedGoogle Scholar
• Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. PPA. 2017;11:1789–1796.
   Web of Science ®Google Scholar
• Sellebjerg F, Barnes D, Filippini G, et al. Chapter 27. Acute relapses of multiple sclerosis. In: Gilhus NE, Barnes MR, Brainin E, editors. European Handbook of Neurological Management. 2nd ed. Vol. 1. Hoboken, NJ: Wiley-Blackwell; 2011.
   Google Scholar
• National Institute of Health and Care Excellence. Multiple sclerosis. Scenario: managing relapse [Internet]. 2018 [cited 2019 Sep]. Available from: https://cks.nice.org.uk/multiple-sclerosis#!scenario:1
   Google Scholar
• Cortese I, Chaudhry V, So YT, et al. Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300.
   PubMed Web of Science ®Google Scholar